Effectiveness and compliance of medication for enhancing immune response in patients with systemic disease (GCF in cyclical neutropenia or insulin treatment in insulin-dependent diabetes) is ascertained by regular monitoring of gingival and periodontal health. This evidence concerns the gene INS and neutropenia.